for mobile/tablet users, please navigate using the menu located below.
  "Perfection is not attainable, but if we chase perfection we can catch excellence."
~Vince Lombardi

Proven track record…

Fund I was established on August 2000 to invest in early stage life science companies within the UK and continental Europe, with a particular focus on biotechnology, medical devices, drug delivery, medical services, diagnostics/ analytical equipment. In each investment, Technomark acted as either lead or co-lead investor in the funding round, structured and negotiated the investment, and coordinated the syndicate building and due diligence process.

Some of the other venture capital firms and institutions with whom we co-invested:
Merlin Biosciences (now Excaliber Fund Managers) - UK
Temasek Capital - Singapore
Friends, Ivory, & Sime - UK
Genechem Management - Montreal, Canada
Avlar BioVentures - UK
Belgian Venture Capital & Private Equity Association
Innoven Parternaires (now IPSA) - Paris, France
Yorkshire Fund Managers - UK


Fund I Portfolio (acquired by)

Amedis Pharmaceuticals (Takeda)
Arakis Ltd. (Sosei)
Biovex Limited (Amgen)
Matrix Therapeutics
Paradigm Therapeutics (Takeda)
Proteom Limited (Amura)
Ranier Limited (Private)
SynGenics (Sosei)